Werbung
AASTROM ( WKN 905286 )!!!
KK 0,68€.; Nachkauf zu 0,7€.
Akt. USA 0,7$
KZ 1,2$ = 1,35€.
Gründe:
- AaStrom ist eine der innovativsten US-Firmen in Sachen Krebsforschung und die letzten News sind vielversprechend
( siehe unten )
- der Chart: Ausbruch steht bevor, steigende Umsätze
- im Moment erfolgreicher Test des ATL´s bei 0,65$!!!
Hier sogar günstiger als in USA!!!
Letzte News:
Aastrom Biosciences Receives Patent for Adult Bone Marrow Stem Cells
- Patent Expands Intellectual Property for Producing Therapeutic Cells -
ANN ARBOR, Mich., Feb. 27 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM - news) announced today that it
received from the U.S. Patent and Trademark Office patent number 6,326,198 entitled, ``Methods and Compositions for the Ex Vivo
Replication of Stem Cells, for the Optimization of Hematopoietic Progenitor Cell Cultures, and for Increasing the Metabolism, GM-CSF
Secretion and/or IL-6 Secretion of Human Stromal Cells.`` This patent provides coverage of Aastrom`s technology for growing or
multiplying human stem cells that are found in adult bone marrow. The new patent focuses on stem cell growth methods that are
enabled by regulated medium delivery and the presence of human stromal cells. The patent also provides claims for the production of
human progenitor cells that are the products of stem cells.
``Aastrom continues to expand its patent portfolio to cover our clinical systems, our devices and our biological processes for growing
human stem and other cells. This new patent extends coverage of Aastrom`s unique perfusion technology that enables the growth of
highly robust human cells outside the body,`` said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. ``The
methods described in our new patent are readily implemented in the automated and GMP-compliant environment of the
AastromReplicell(TM) System, strategically positioning Aastrom as a leader in the cell therapy field.``
The stem cells found in bone marrow have been shown to be powerful therapeutic tools, with clinical potential in treatments that include
re-establishing normal blood and immune systems in cancer patients, and the generation of connective tissues, such as bone.
Aastrom`s business plan is to provide commercial access to these valuable therapeutic cells for multiple medical indications.
About Aastrom Biosciences, Inc.
Aastrom is a leader in the development of proprietary cell therapeutic products based on its dual-technology platforms: patented
``single-pass perfusion`` providing cells with excellent biological function, and patented GMP-compliant system automation facilitating
the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicell(TM) System
that is designed to uniquely standardize and automate the processes involved in producing high quality therapeutic cells. Aastrom is
developing a range of cell therapeutic products, including the Dendricell(TM) products for use in the dendritic cell-based cancer vaccine
market, and the OC-I bone progenitor cell production product for the treatment of degenerative bone diseases such as osteoporosis.
The AastromReplicell(TM) System, the SC-I bone marrow and the CB-I cord blood cell production products have previously received CE
Mark approval necessary for European marketing, and are in late-stage U.S. clinical trials. These products are not available for sale at
this time in the U.S., except for research or investigational use. In addition, the DC-I and DCV-I dendritic cell production products have
recently received CE Mark approval necessary for European marketing, and are available for sale to the research market in the U.S.
Please visit our website at www.aastrom.com
This document contains forward-looking statements, including without limitation, statements regarding product development objectives,
potential product applications and potential advantages of the AastromReplicell(TM) System, which involve certain risks and
uncertainties. The forward-looking statements are also identified through use of the words ``intend,`` ``plan,`` and other words of similar
meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors
that may result in differences are the results obtained from clinical trial and development activities, the availability of resources,
competitive developments and the allocation of resources among different potential uses. These and other significant factors are
discussed in greater detail in Aastrom`s Annual Report on Form 10-K, and other filings with the Securities and Exchange Commission.
CONTACTS: Kris M. Maly Noonan/Russo Communications, Inc.
Investor Relations Manager Phone: 212-696-4455
Aastrom Biosciences, Inc. Glenn Silver, ext. 271 (media)
Phone: 734-930-5777 David Walsey, ext. 230 (investors)
SOURCE: Aastrom Biosciences, Inc.
MfG
Star Ikone ;)
KK 0,68€.; Nachkauf zu 0,7€.
Akt. USA 0,7$
KZ 1,2$ = 1,35€.
Gründe:
- AaStrom ist eine der innovativsten US-Firmen in Sachen Krebsforschung und die letzten News sind vielversprechend
( siehe unten )
- der Chart: Ausbruch steht bevor, steigende Umsätze
- im Moment erfolgreicher Test des ATL´s bei 0,65$!!!
Hier sogar günstiger als in USA!!!
Letzte News:
Aastrom Biosciences Receives Patent for Adult Bone Marrow Stem Cells
- Patent Expands Intellectual Property for Producing Therapeutic Cells -
ANN ARBOR, Mich., Feb. 27 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM - news) announced today that it
received from the U.S. Patent and Trademark Office patent number 6,326,198 entitled, ``Methods and Compositions for the Ex Vivo
Replication of Stem Cells, for the Optimization of Hematopoietic Progenitor Cell Cultures, and for Increasing the Metabolism, GM-CSF
Secretion and/or IL-6 Secretion of Human Stromal Cells.`` This patent provides coverage of Aastrom`s technology for growing or
multiplying human stem cells that are found in adult bone marrow. The new patent focuses on stem cell growth methods that are
enabled by regulated medium delivery and the presence of human stromal cells. The patent also provides claims for the production of
human progenitor cells that are the products of stem cells.
``Aastrom continues to expand its patent portfolio to cover our clinical systems, our devices and our biological processes for growing
human stem and other cells. This new patent extends coverage of Aastrom`s unique perfusion technology that enables the growth of
highly robust human cells outside the body,`` said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. ``The
methods described in our new patent are readily implemented in the automated and GMP-compliant environment of the
AastromReplicell(TM) System, strategically positioning Aastrom as a leader in the cell therapy field.``
The stem cells found in bone marrow have been shown to be powerful therapeutic tools, with clinical potential in treatments that include
re-establishing normal blood and immune systems in cancer patients, and the generation of connective tissues, such as bone.
Aastrom`s business plan is to provide commercial access to these valuable therapeutic cells for multiple medical indications.
About Aastrom Biosciences, Inc.
Aastrom is a leader in the development of proprietary cell therapeutic products based on its dual-technology platforms: patented
``single-pass perfusion`` providing cells with excellent biological function, and patented GMP-compliant system automation facilitating
the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicell(TM) System
that is designed to uniquely standardize and automate the processes involved in producing high quality therapeutic cells. Aastrom is
developing a range of cell therapeutic products, including the Dendricell(TM) products for use in the dendritic cell-based cancer vaccine
market, and the OC-I bone progenitor cell production product for the treatment of degenerative bone diseases such as osteoporosis.
The AastromReplicell(TM) System, the SC-I bone marrow and the CB-I cord blood cell production products have previously received CE
Mark approval necessary for European marketing, and are in late-stage U.S. clinical trials. These products are not available for sale at
this time in the U.S., except for research or investigational use. In addition, the DC-I and DCV-I dendritic cell production products have
recently received CE Mark approval necessary for European marketing, and are available for sale to the research market in the U.S.
Please visit our website at www.aastrom.com
This document contains forward-looking statements, including without limitation, statements regarding product development objectives,
potential product applications and potential advantages of the AastromReplicell(TM) System, which involve certain risks and
uncertainties. The forward-looking statements are also identified through use of the words ``intend,`` ``plan,`` and other words of similar
meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors
that may result in differences are the results obtained from clinical trial and development activities, the availability of resources,
competitive developments and the allocation of resources among different potential uses. These and other significant factors are
discussed in greater detail in Aastrom`s Annual Report on Form 10-K, and other filings with the Securities and Exchange Commission.
CONTACTS: Kris M. Maly Noonan/Russo Communications, Inc.
Investor Relations Manager Phone: 212-696-4455
Aastrom Biosciences, Inc. Glenn Silver, ext. 271 (media)
Phone: 734-930-5777 David Walsey, ext. 230 (investors)
SOURCE: Aastrom Biosciences, Inc.
MfG
Star Ikone ;)
